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Critical to the eﬀective implementation of high throughput methods
of synthesis is the necessity for a signiﬁcant supporting level of
automation. There are a number of critical issues associated with
the successful introduction, and supporting role, of automation of
small molecule chemical synthesis. Clearly there are needs for
automation to increase drug candidate synthesis throughput.
Automation of repetitive and laborious tasks associated with the
synthesis process can release skilled chemists to apply their talents
to the more challenging investigational aspects of developing new
synthetic protocols. This provides continuity in the compound
supply pipeline and ensures an optimal use of the automated
platform for compound production. The very high ﬁdelity of
performing repetitive processes that can be managed through
automation also removes some of the limitations and errors
associated with more fallible human operators. This can include
very diﬃcult tasks associated with tracking data, and general
information and inventory management. Taken collectively, these
attributes associated with automation can lead to greater eﬃcien-
cies, throughputs and improved allocation of human resources with
concomitant reductions in costs associated with current day and
future drug discovery. In our library development/synthesis para-
digm, we feel that automation support must be invoked early in the
process and that this automation support must continue throughout
the project.
Introduction
High throughput synthesis, aided by combinatorial tech-
niques, automated synthesis and parallel puriﬁcation, has
contributed a great deal to making the synthetic medic-
inal chemist more eﬃcient. However, it is not as clear
that these techniques alone have made drug discovery
easier or more successful. Other tools have become
available to aid in library design, while cheminformatics
provide a rich base for knowledge-driven discovery.
Structure-based design has been available for several
decades, but has enjoyed a rebirth due to the increased
sophistication of modeling software and the availability
of many attractive target crystal structures.
The guiding principle of medicinal chemists is the acqui-
sition of knowledge. The quandary is often in choosing
which molecules to make. These should be chosen in
a manner that maximizes the understanding of the
relationship between chemical structure and biologi-
cal activity. The compounds should be ‘drug-like’ in
character and should eﬀectively address ongoing hypoth-
eses regarding the rules for improving activity in a given
series [1–3].
Are combinatorial chemistry tools advancing
discovery?
There are inherent limitations in the available tech-
nologies. There are activation barriers to learning new
systems, particularly if end-user intimacy is sacriﬁced.
Medicinal chemists ﬁnd themselves dependent on other
technologies and may be uncomfortable in that role. As
end-users they must judge the adequacy of the particular
tool for the particular application. And in many cases
will ﬁnd that the new tools may be only partially
enabling in accessing the molecules that they need. There
are also potential traps if tools are misplaced. Several
questions need to be addressed:
. Is the library design diverse and drug-like?
. Is the chemistry accessible through automation?
. Am I overloaded with data, much of which is
irrelevant?
. Is there non-stochastic noise in the data causing me
to miss something important?
Any or all of these factors can lead to the neutralization
of enablement.
Genome-based drug discovery
In principle, the human genome provides more than
100000 potential targets. However, before embarking
on genome-based drug discovery, we need to assess a
number of important questions.
. How many are drugable?
. For what diseases?
. How do we choose intelligently?
. How do we validate those, which are chosen?
. How long will it take?
. What will it cost?
Unfortunately, many of these novel targets are extremely
knowledge poor. Indeed, building a knowledge base on a
novel target is a very large investment of both time and
money.
Large library approach
Figure 1 shows a split-pool combinatorial library
comprised of over 2 million compounds [4]. This library
of polycyclic shikimic acid analogues was elegantly
synthesized with great attention to quality control.
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57See [4] for an excellent account of this elegant synthetic
work. However, this library was screened in three
separate assays. No activity was observed in the ﬁrst
two, and in the third assay the best activity was
EC50¼50mM as an activator of the TGF--responsive
mammalian reporter gene. This work highlights the
dangers involved in screening mixtures of compounds.
Unfortunately, only a very few biologically active small
molecules are highly selective for their targets. Productive
libraries are probably best built on known biologically
active small molecules. The goal should be to identify
compounds which do the following:
. Exhibit conﬁrmed activity in at least one HTS
assay.
. Have been ﬁltered to remove objectionable
functionality.
. Have passed selected ‘drug-like’ algorithms.
. Have passed a ‘non-toxic’ algorithm.
At this point enhancement of potency and selectivity for
target identiﬁcation can be achieved with a series of
synthesize, test, design cycles.
Systematic synthesis development
The development of synthetic strategies needs to be care-
fully systematized to maximize eﬃciency and chemistry
reliability. This can best be accomplished by following a
tightly deﬁned series of developmental steps.
. Replicate model literature reactions.
. ‘Parallelize’ the development of solid phase and
solution phase synthesis.
. Have a clear deﬁnition of experimental expectations:
. Rigorous analysis using internal standards.
. Run experiments in multiplicate.
. Formal experimental design and optimization:
. Select variables.
. Stage early on automated platform.
. Iterate.
. Avoid restricting the options too early.
. Allow the chemistry to guide the use of appropriate
automation rather than forcing the chemistry to
work on an existing automated platform.
Overall, we expect automation to reproduce those
actions faithfully, which are performed manually by
chemists. This reliability should remain even in the face
of complex syntheses. Automated platforms should not be
unduly fettered by a complex learning curve. Of course,
of necessity the automation must be priced to ﬁt the
research budget while at the same time remaining ﬁt for
purpose. We make every eﬀort to use the appropriate-
automated technique from the very beginnings of
exploratory chemistry, chemistry development, library
Figure 1. Full matrix combinatorics using split-pool organic synthesis.
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(up to 4K). Of course, this assures that our chemistry is
well in hand for the eventuality of hit re-synthesis.
Overview of the available automation platforms
Many commercially available synthesis platforms lacked
the ﬂexibility sought by our group:
. Limited capability to support parallel addition of
reagents, and solvents.
. Most lacked functional modularity.
. Most lacked software and hardware ﬂexibility.
Therefore, we sought an alliance with an automation
partner for the purpose of designing and building a
reliable ﬂexible synthesis platform [6]. Figure 2 shows
the prototype synthesizer and the scale up module
designed in collaboration with Zymark Corporation.
The features include capability for the following:
. Pooled reaction chemistries.
. Multiple programmable wash cycles.
. Simple menu-driven software, which is easily
modiﬁed.
. Customized reaction vessels (not size limited) up to
1litre capacity.
Also included in this collaboration was a production level
instrument for library synthesis and hit re-synthesis
(ﬁgure 3).
This synthesizer features 96 reaction vessels arranged in
four blocks of 24. Each block can be individually tem-
perature controlled over a range from  78 to þ150 C,
while being kept under an inert environment. Reagents
may be added serially or in parallel and all wash steps are
done in parallel [5]. The diversity reagent preparation
for this instrument can be performed on a specially
modiﬁed BenchMate
TM (Zymark Corp., Hopkinton,
MA, USA) workstation with racks that are compatible
with the production synthesizer (ﬁgure 4).
Exploratory chemistry and development chemistry
are routinely performed on one of several Argonaut
Technologies Quest
 205 (larger scale 10 reaction
vessels) or Quest
 210 (smaller scale 20 reaction vessels)
semi-automated platforms (ﬁgure 5).
The authors have recently acquired a Myriad Discoverer
3000Synthesizer
TM(Mettler-ToledoCorp.,VernonHills,
IL, USA) to strengthen our automation capabilities for
solution-phase synthesis. This platform is fully automated
and has the capability of performing 24 individual reac-
tions simultaneously. It is also suited with modiﬁed
reaction vessels to operate in the solid phase chemistry
mode (ﬁgure 6).
Figure 2. (Left) Zymark prototype synthesizer; (Right) scale-up module.
Figure 3. Zymark production-level synthesizer. Figure 4. BenchMate
TM workstation.
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Myriad Allex
TM liquid handler for solution phase extrac-
tion workups of products from the Discoverer (ﬁgure 7).
The main workhorse for library synthesis are a pair
of Argonaut Trident
TM automated synthesizers. Each
instrument is capable of synthesizing 192 compounds/run,
or 96 compounds/run on a larger scale (10ml). This fully
automated platform contains many of the features of the
Zymark synthesizer described above. The design of this
instrument was chemistry-driven and it is invaluable for
our work. The software has gone through numerous
upgrades and is extremely chemist oriented (ﬁgures 8
and 9).
The Trident
 also has a companion Trident
 SPS Work-
station, which is manufactured by Zinsser Analytic
GmbH (Germany). This workstation is compatible with
Trident
 reaction cassettes but is easily conﬁgurable to
any rack which is desired. This station also features
automatic resin dispensing to Trident
 reaction cassette
blocks (ﬁgure 10).
Figure 5. Argonaut Quest
 210.
Figure 8. Argonaut Trident
.
Figure 6. Myriad Discoverer 3000 Synthesizer
TM.
Figure 9. For small complex molecule synthesis.
Figure 7. Myriad Allex
TM.
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TM Microwave Synthesizer (Personal
Chemistry, Boston, MA, USA) is an automated serial
instrument with liquid handler. The technology oﬀers
the advantage of accelerating the rate of thermally
driven reactions by as much as 100-fold over normal
heating techniques. One frequently observes higher
chemical conversion, greater purity and minimization
of undesired side reactions. This instrument has proven
itself repeatedly to have great value in our synthesis
group (ﬁgure 11).
With the many tools available, we ﬁnd that the diﬃculty
can often lie in choosing the right tool for the job. This
requires striking a balance between becoming overly
systematic as a means of limiting risk. However, this
can also mean that one must balance the danger of
becoming prescriptive to the exclusion of creativity.
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